Iceland· IS-EU/1/25/1989/001-002
IMAAVY
A nipocalimab product containing nipocalimab, registered in Iceland by Janssen Cilag International. The same ATC class is registered in 8 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Nipocalimab is registered in 8 of 19 countries.
Countries holding a registration under ATC L04AL03 (nipocalimab), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 6 of them publish a price we can compare per daily dose
Nipocalimab · ATC L04AL03
8 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Switzerlandprice
- United Statesprice
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Nipocalimab
- Manufacturer
- Janssen Cilag International
- Country
- Iceland (IS)
- ATC code
- L04AL03
- ATC class
- Nipocalimab
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Nipocalimab in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesIMAAVYJanssen Biotech, Inc.
- CzechiaIMAAVYJanssen-Cilag International N.V., Beerse
- BelgiumImaavy 185 mg/mlJanssen-Cilag International
- SwedenImaavy 185 mg/ml Koncentrat till infusionsvätska, lösningJanssen-Cilag International NV
- IrelandImaavy 185 mg/mL concentrate for solution for infusionJanssen-Cilag International NV
- FinlandImaavyJanssen Cilag International
- PolandImaavyJanssen-Cilag International N.V.
- SwitzerlandImaavy 1200 mg/6.5 ml (185 mg/ml), Konzentrat zur Herstellung einer InfusionslösungJanssen-Cilag AG
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Imaavy
- Norway · Imaavy
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d0f09b55-2bb1-4d5b-a5f1-eaa84ec0fdd2 GET /v1/drugs/d0f09b55-2bb1-4d5b-a5f1-eaa84ec0fdd2?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Innrennslisþykkni, lausn",
"source": "lyfjastofnun",
"atc_raw": "L04AL03",
"marketed": false,
"strength": "185 mg/ml",
"ma_number": "EU/1/25/1989/001-002",
"substance": "Nipocalimab",
"other_info": null,
"legal_status": "(R) Lyfseðilsskylt\r\n(H) Sjúkrahúsmerkt",
"ma_issued_serial": "45989"
}See everything about nipocalimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.